Stay updated with breaking news from Objective Response Rate. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Everest Medicines returned rights for Trodelvy to Immunomedics. Nanchang Jemincare out-licensed global rights for its prostate cancer candidate to Genentech in a $650 million deal.
SUZHOU, China, Aug. 9, 2022 /PRNewswire/ -- First Patient Dosed in Phase II Study of KN046 Combined with Axitinib for the First Line Treatment of Advanced Non-Small Cell Lung Cancer
Investegate announcements from Hutchmed China Ltd, Preliminary results from SAVANNAH Phase 2 Trial
BASKING RIDGE, N.J. and SAN DIEGO, July 06, 2022 -- Caladrius Biosciences, Inc. , a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse... | July 6, 2022
Globally first dual immune checkpoint inhibitor bi-specific antibody approved for marketing China's first immunotherapy bi-specific antibody approved for...